Blood Gas Analyzer Supports Rapid Critical Point-of-Care Measurements
|
By LabMedica International staff writers Posted on 02 Oct 2014 |

Image: The new Proxima in-line patient-dedicated arterial blood gas analyzer incorporates the Proxima Sensor (in foreground) and a dedicated bedside monitor (Photo courtesy of Sphere Medical).

Image: The miniaturized Proxima Sensor is integrated into a patient’s arterial line to be used for directly monitoring blood gases and electrolytes, per 72 hour period as many times as required (Photo courtesy of Sphere Medical).

Image: The miniaturized Proxima Sensor is integrated into a patient’s arterial line to be used for directly monitoring blood gases and electrolytes (Photo courtesy of Sphere Medical).
A novel miniature, patient dedicated in-line blood gas analyzer improves critical care by providing near real-time measurements at laboratory analyzer accuracy.
Sphere Medical (Cambridge, UK), innovator in critical care monitoring and diagnostics equipment, has launched its cutting-edge analyzer, Proxima, at the Association of Anesthetists of Great Britain and Ireland Annual Congress (AAGBI) 2014 (September 17-19, 2014, Harrogate, UK). The Proxima miniaturized blood gas analyzer uniquely delivers rapid, frequent results at patient bedside to enable fast response, proactive critical care—closer control of therapeutic response leading to improved patient outcome, as well as to reduced overall cost of care.
CE-marked and designed for critical care environments, the Proxima System incorporates a dedicated bedside monitor and the Proxima Sensor integrated into a patient’s arterial line. This enables blood to be measured directly at point-of-care without need to leave the patient or manipulate samples and cartridges, which can add to the workload of frontline care staff. Measured to laboratory analyzer accuracy, results are rapidly displayed on the bedside monitor and can be electronically transferred for permanent record.
Simple to use, Proxima enables closed blood sampling and is operated via the touch screen interface of its bedside monitor. When a blood gas analysis is required, blood is withdrawn from the patient directly into the Proxima Sensor without need to open the line, take a sample, and walk away for analysis. Once analysis is completed, all blood is returned to the patient, thereby ensuring blood conservation and reducing the possibility of hospital acquired anemia and subsequent transfusions. A Proxima Sensor is a disposable transducer which can be used for monitoring blood gases and electrolytes over a 72 hour period as many times as required. The system also carries out all quality control checks that would be undertaken on a traditional blood gas analyzer to ensure validity of test results. It also includes a facility to be challenged with liquid controls.
Dr. Tom Clutton-Brock, University Hospital Birmingham, said, “Rapid return of data and swift response to changing blood gases is as essential in patient care as the continual measurement of blood pressure. Fast feedback and response could have a real impact on efficiently stabilizing patients or weaning them from mechanical ventilation.” “Frequent measurement of arterial blood samples is a key component in the effective management of patients in the critical care environment, particularly those that are unstable,” said Dr. Wolfgang Rencken, CEO of Sphere Medical, “we have developed and launched Proxima to keep the caregiver by the patient, conserve blood, and rapidly return blood gas results to aid early decision making and closer control of therapy for critically ill patients—all of which will ultimately improve patient outcomes.”
Also at AAGBI 2014, Sphere Medical sponsored an industry seminar where Dr. Clutton-Brock presented on “True Point-of-Care Testing,” discussing challenges of maintaining control of patient physiology in the ITU, focusing on the frequency of arterial blood sample testing ideally required, and associated limitations such as staff time involved, costs, and blood conservation. He also considered how matters might change if these limitations were removed.
Related Links:
Sphere Medical
Sphere Medical (Cambridge, UK), innovator in critical care monitoring and diagnostics equipment, has launched its cutting-edge analyzer, Proxima, at the Association of Anesthetists of Great Britain and Ireland Annual Congress (AAGBI) 2014 (September 17-19, 2014, Harrogate, UK). The Proxima miniaturized blood gas analyzer uniquely delivers rapid, frequent results at patient bedside to enable fast response, proactive critical care—closer control of therapeutic response leading to improved patient outcome, as well as to reduced overall cost of care.
CE-marked and designed for critical care environments, the Proxima System incorporates a dedicated bedside monitor and the Proxima Sensor integrated into a patient’s arterial line. This enables blood to be measured directly at point-of-care without need to leave the patient or manipulate samples and cartridges, which can add to the workload of frontline care staff. Measured to laboratory analyzer accuracy, results are rapidly displayed on the bedside monitor and can be electronically transferred for permanent record.
Simple to use, Proxima enables closed blood sampling and is operated via the touch screen interface of its bedside monitor. When a blood gas analysis is required, blood is withdrawn from the patient directly into the Proxima Sensor without need to open the line, take a sample, and walk away for analysis. Once analysis is completed, all blood is returned to the patient, thereby ensuring blood conservation and reducing the possibility of hospital acquired anemia and subsequent transfusions. A Proxima Sensor is a disposable transducer which can be used for monitoring blood gases and electrolytes over a 72 hour period as many times as required. The system also carries out all quality control checks that would be undertaken on a traditional blood gas analyzer to ensure validity of test results. It also includes a facility to be challenged with liquid controls.
Dr. Tom Clutton-Brock, University Hospital Birmingham, said, “Rapid return of data and swift response to changing blood gases is as essential in patient care as the continual measurement of blood pressure. Fast feedback and response could have a real impact on efficiently stabilizing patients or weaning them from mechanical ventilation.” “Frequent measurement of arterial blood samples is a key component in the effective management of patients in the critical care environment, particularly those that are unstable,” said Dr. Wolfgang Rencken, CEO of Sphere Medical, “we have developed and launched Proxima to keep the caregiver by the patient, conserve blood, and rapidly return blood gas results to aid early decision making and closer control of therapy for critically ill patients—all of which will ultimately improve patient outcomes.”
Also at AAGBI 2014, Sphere Medical sponsored an industry seminar where Dr. Clutton-Brock presented on “True Point-of-Care Testing,” discussing challenges of maintaining control of patient physiology in the ITU, focusing on the frequency of arterial blood sample testing ideally required, and associated limitations such as staff time involved, costs, and blood conservation. He also considered how matters might change if these limitations were removed.
Related Links:
Sphere Medical
Latest Technology News
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
- AI-Generated Sensors Open New Paths for Early Cancer Detection
- Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
- AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
- Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer
- Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers
- Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Channels
Molecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







